AMAG Pharmaceuticals Inc. (AMAG)’s Financial Results Comparing With ImmuCell Corporation (NASDAQ:ICCC)

Both AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and ImmuCell Corporation (NASDAQ:ICCC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AMAG Pharmaceuticals Inc. 432.42M 0.72 233.32M -4.92 0.00
ImmuCell Corporation 12.52M 3.77 1.96M -0.42 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of AMAG Pharmaceuticals Inc. and ImmuCell Corporation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of AMAG Pharmaceuticals Inc. and ImmuCell Corporation.

Net Margins Return on Equity Return on Assets
AMAG Pharmaceuticals Inc. -53.96% -8.8% -4.3%
ImmuCell Corporation -15.65% -10.2% -7%

Risk & Volatility

A beta of 0.33 shows that AMAG Pharmaceuticals Inc. is 67.00% less volatile than Standard & Poor’s 500. Competitively, ImmuCell Corporation’s 18.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.18 beta.

Liquidity

AMAG Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 3.2 and 3 respectively. The Current Ratio and Quick Ratio of its competitor ImmuCell Corporation are 2.5 and 1.6 respectively. AMAG Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to ImmuCell Corporation.

Analyst Recommendations

AMAG Pharmaceuticals Inc. and ImmuCell Corporation Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AMAG Pharmaceuticals Inc. 0 1 0 2.00
ImmuCell Corporation 0 0 0 0.00

The average target price of AMAG Pharmaceuticals Inc. is $14, with potential upside of 51.35%.

Insider and Institutional Ownership

Institutional investors held 0% of AMAG Pharmaceuticals Inc. shares and 19.1% of ImmuCell Corporation shares. AMAG Pharmaceuticals Inc.’s share held by insiders are 2.9%. Insiders Comparatively, held 4.9% of ImmuCell Corporation shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AMAG Pharmaceuticals Inc. 3.45% -8.81% -28.41% -36.15% -50.37% -25.02%
ImmuCell Corporation -3.75% -7.09% -13.6% -25.18% -12.87% -12.58%

For the past year ImmuCell Corporation has weaker performance than AMAG Pharmaceuticals Inc.

Summary

ImmuCell Corporation beats on 6 of the 11 factors AMAG Pharmaceuticals Inc.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.